Menu Search
Equities

Vcanbio Cell & Gene Engineering Corp Ltd

600645:SHH

Vcanbio Cell & Gene Engineering Corp Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)18.75
  • Today's Change-2.96 / -13.63%
  • Shares traded28.61m
  • 1 Year change-9.02%
  • Beta1.3143
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Vcanbio Cell & Gene Engineering Corp Ltd's net income fell -5.78% from 112.99m to 106.45m despite flat revenues.
Gross margin68.10%
Net profit margin6.38%
Operating margin8.53%
Return on assets1.90%
Return on equity2.94%
Return on investment2.68%
More ▼

Cash flow in CNYView more

In 2023, Vcanbio Cell & Gene Engineering Corp Ltd increased its cash reserves by 14.48%, or 200.02m. The company earned 299.02m from its operations for a Cash Flow Margin of 18.81%. In addition the company used 90.49m on investing activities and also paid 18.73m in financing cash flows.
Cash flow per share--
Price/Cash flow per share--
Book value per share7.73
Tangible book value per share5.88
More ▼

Balance sheet in CNYView more

Vcanbio Cell & Gene Engineering Corp Ltd uses little debt in its capital structure as supported by a debt to capital ratio of 2.96%.
Current ratio1.66
Quick ratio1.48
Total debt/total equity0.031
Total debt/total capital0.0296
More ▼

Growth rates in CNY

Year on year, growth in earnings per share excluding extraordinary items dropped -5.78%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
EPS growth(5 years)8.69
EPS (TTM) vs
TTM 1 year ago		-15.88
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.